• 上海交通大學(xué)附屬第一人民醫(yī)院檢驗(yàn)科（上海 200080）;

引用本文： 藺麗慧,李莉. 過(guò)敏性哮喘及其它過(guò)敏性疾病免疫生物治療研究進(jìn)展. 中國(guó)呼吸與危重監(jiān)護(hù)雜志, 2009, 09(3): 300-302. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國(guó)呼吸與危重監(jiān)護(hù)雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Bousquet J，Dahl R，Khaltaev N.Global alliance against chronic respiratory diseases.Allergy，2007，62：216-223.
2. Holgate S，Casale T，Wenzel S，et al.The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.J Allergy Clin Immunol，2005，115：459-465.
3. Bradding P，Walls AF，Holgate ST.The role of the mast cell in the pathophysiology of asthma.J Allergy Clin Immunol，2006，117：1277-1284.
4. Cruse G，Kaur D，Yang W，et al.Activation of human lung mast cells by monomeric immunoglobulin E.Eur Respir J，2005，25：858-863.
5. Slavin RG，F(xiàn)erioli C，Tannenbaum SJ，et al.Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.J Allergy Clin Immunol，2009，123：107-113.
6. Lin H，Boesel KM，Griffith DT，et al.Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.J Allergy Clin Immunol，2004，113：297-302.
7. Djukanovi? R，Wilson SJ，Kraft M，et al.Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.Am J Respir Crit Care Med，2004，170：583-593.
8. Soler M.Anti-IgE antibodies in the treatment of allergic diseases.Allergol Immunol Clin，2002，42：45-49． 8 Hayashi N，Tsukamoto Y，Sallas WM，et al.A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.Br J Clin Pharmacol，2007，63：548-561.
9. Dodig S，Richter D，Cepelak I.Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.Acta Pharm，2005，55：123-138.
10. Saxon A，Kepley CL，Zhang K，et al."Accentuate the negative，eliminate the positive"：engineering allergy therapeutics to block allergic reactivity through negative signaling.J Allergy Clin Immunol，2008，121：320-325.
11. Kepley CL，Taghavi S，Mackay G，et al.Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes.J Biol Chem，2004，279：35139-35149.
12. Daëron M，Malbec O，Latour S，et al.Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.J Clin Invest，1995，95：577-585.
13. Zhu D，Kepley CL，Zhang K，et al.A novel human immunoglobulin Fcγ–Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation.Nat med，2005，11：446-449.
14. Zhang K，Kepley CL，Terada T，et al.Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein.J Allergy Clin Immunol，2004，114：321-327.
15. Kepley CL，Zhang K，Zhu D，et al.Fc?RI-Fc?RII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells.Clin Immunol，2003，108：89-94.
16. Yamada T，Zhu D，Zhang K，et al.Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc?-Fc? chimeric protein.J Biol Chem，2003，278：32818-32824.
17. Saxon A，Zhu D，Zhang K，et al.Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases.Curr Opin Allergy Clin Immunol，2004，4：563-568.
18. Allen LC，Kepley CL，Saxon A，et al.Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions.J Allergy Clin Immunol，2007，120：462-468.
19. Zhu D，Kepley CL，Zhang K，et al.A chimeric human-cat fusion protein blocks cat-induced allergy.Nat Med，2005，11：446-449.
20. Zhang K，Zhu D，Kepley CL，et al.Chimeric human fcγ-allergen fusion proteins in the prevention of allergy.Immunol Allergy Clin North Am，2007，27：93-103.
21. Terada T，Zhang K，Belperio J，et al.A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic，pulmonary，and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1，the major cat allergen.Clin Immunol，2006，120：45-56.
  1. 1. Bousquet J，Dahl R，Khaltaev N.Global alliance against chronic respiratory diseases.Allergy，2007，62：216-223.
  2. 2. Holgate S，Casale T，Wenzel S，et al.The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.J Allergy Clin Immunol，2005，115：459-465.
  3. 3. Bradding P，Walls AF，Holgate ST.The role of the mast cell in the pathophysiology of asthma.J Allergy Clin Immunol，2006，117：1277-1284.
  4. 4. Cruse G，Kaur D，Yang W，et al.Activation of human lung mast cells by monomeric immunoglobulin E.Eur Respir J，2005，25：858-863.
  5. 5. Slavin RG，F(xiàn)erioli C，Tannenbaum SJ，et al.Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.J Allergy Clin Immunol，2009，123：107-113.
  6. 6. Lin H，Boesel KM，Griffith DT，et al.Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.J Allergy Clin Immunol，2004，113：297-302.
  7. 7. Djukanovi? R，Wilson SJ，Kraft M，et al.Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.Am J Respir Crit Care Med，2004，170：583-593.
  8. 8. Soler M.Anti-IgE antibodies in the treatment of allergic diseases.Allergol Immunol Clin，2002，42：45-49． 8 Hayashi N，Tsukamoto Y，Sallas WM，et al.A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab.Br J Clin Pharmacol，2007，63：548-561.
  9. 9. Dodig S，Richter D，Cepelak I.Anti-IgE therapy with omalizumab in asthma and allergic rhinitis.Acta Pharm，2005，55：123-138.
  10. 10. Saxon A，Kepley CL，Zhang K，et al."Accentuate the negative，eliminate the positive"：engineering allergy therapeutics to block allergic reactivity through negative signaling.J Allergy Clin Immunol，2008，121：320-325.
  11. 11. Kepley CL，Taghavi S，Mackay G，et al.Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes.J Biol Chem，2004，279：35139-35149.
  12. 12. Daëron M，Malbec O，Latour S，et al.Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors.J Clin Invest，1995，95：577-585.
  13. 13. Zhu D，Kepley CL，Zhang K，et al.A novel human immunoglobulin Fcγ–Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation.Nat med，2005，11：446-449.
  14. 14. Zhang K，Kepley CL，Terada T，et al.Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein.J Allergy Clin Immunol，2004，114：321-327.
  15. 15. Kepley CL，Zhang K，Zhu D，et al.Fc?RI-Fc?RII coaggregation inhibits IL-16 production from human Langerhans-like dendritic cells.Clin Immunol，2003，108：89-94.
  16. 16. Yamada T，Zhu D，Zhang K，et al.Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc?-Fc? chimeric protein.J Biol Chem，2003，278：32818-32824.
  17. 17. Saxon A，Zhu D，Zhang K，et al.Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases.Curr Opin Allergy Clin Immunol，2004，4：563-568.
  18. 18. Allen LC，Kepley CL，Saxon A，et al.Modifications to an Fcgamma-Fcvarepsilon fusion protein alter its effectiveness in the inhibition of FcvarepsilonRI-mediated functions.J Allergy Clin Immunol，2007，120：462-468.
  19. 19. Zhu D，Kepley CL，Zhang K，et al.A chimeric human-cat fusion protein blocks cat-induced allergy.Nat Med，2005，11：446-449.
  20. 20. Zhang K，Zhu D，Kepley CL，et al.Chimeric human fcγ-allergen fusion proteins in the prevention of allergy.Immunol Allergy Clin North Am，2007，27：93-103.
  21. 21. Terada T，Zhang K，Belperio J，et al.A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic，pulmonary，and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1，the major cat allergen.Clin Immunol，2006，120：45-56.

  • 上一篇

    一線三甲醫(yī)院汶川地震420例骨折住院傷員分類(lèi)救治情況分析

  • 下一篇

    汶川地震四川省衛(wèi)生應(yīng)急救援成效分析